Colorectal cancer is a major, global healthcare burden and, after lung cancer, is the most common cause of cancer death in Europe.

It is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and 700,000 deaths worldwide.

Mandated Screening
- The EU recommends colorectal cancer screening in all its member states, and a number of European countries have implemented screening programs.
- The most frequently used first line test for colorectal cancer screening across Europe is the immunochemical faecal occult bleeding test (FIT).

The Importance of Screening
- Early diagnosis can save lives.
- If diagnosed at stage I, colorectal cancer patients have an average 97% five-year survival rate.
  - Currently fewer than one in ten are diagnosed at this stage.
- If colorectal cancer is not caught until it has spread (stage IV), the chances of surviving five years or more falls to just 7%.
- Early diagnosis not only saves lives; it is also more cost effective. Treatment following late stage diagnosis is almost always costlier than treating patients with early stage disease.

The Challenges of Colorectal Cancer Screening
- Patients with a positive FIT score are referred for colonoscopy. However, approximately 94.8% of people who test FIT positive do not have colorectal cancer.
  - This means there are a number of unnecessary expensive and invasive colonoscopies being performed; placing a severe burden on both the patient and the healthcare system.

There is a significant lack of capacity within healthcare systems, which means many countries are struggling to meet colonoscopy demand.
The Nu.Q™ Colorectal Cancer Screening Triage Test (Nu.Q™ Triage Test) has been developed by Volition, a life sciences company focused on developing diagnostic tests for cancer, at its laboratories in Belgium in conjunction with Hvidovre Hospital (University of Copenhagen).

Patients with a positive FIT score could subsequently be given the blood-based Nu.Q™ Triage Test. This unique test has demonstrated the potential to reduce colonoscopies by up to 25% whilst maintaining almost 97% detection of colorectal cancer. The Nu.Q™ Triage Test is the first CE Marked product in a pipeline of cancer screening tests Volition hopes to bring to market.

"If diagnosed early, colorectal cancer is highly treatable and in some cases curable. Unfortunately, embarrassment and lack of awareness surrounding this cancer is one of the reasons it remains the 2nd highest killer of men and women across Europe. Simple, effective cancer diagnostic tools that people are willing to use could change the prognosis of colorectal cancer forever."

Jola Gore-Booth
Founder/CEO of Europa Colon

Empowering Reassurance

volitionrx.com